权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Combination Therapy of Aspirin and Apyrase for Stroke

阿司匹林和腺苷三磷酸双磷酸酶联合治疗中风

基本信息

批准号：
7996413
负责人：
RIDONG CHEN
金额：
$ 28.76万
依托单位：
APT THERAPEUTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-28 至 2013-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7996413
关键词：
Academy Acute American American Heart Association Animal Model Animals Anti-Inflammatory Agents Anti-inflammatory Antiplatelet Drugs Apyrase Aspirin Autologous Blood Blood Clot Blood Platelets Blood Vessels Blood coagulation Brain Cardiovascular system Cause of Death Cell Culture Techniques Cell Line Cell surface Cerebral hemisphere hemorrhage Cerebrovascular Disorders Cerebrum Chinese Hamster Ovary Cell Clinic Clinical Clinical Data Clinical Trials Combined Modality Therapy Computer Assisted Culture Media Dose Endothelial Cells Engineering Enzymes Exhibits Fibrinolytic Agents Funding Future Goals Grant Guidelines Hemorrhage Hospitalization Hour Human Industry Infarction Injury Intervention Intracranial Hemorrhages Ischemia Ischemic Stroke Laboratories Lilly brand of abciximab Lung Transplantation Metastatic Neoplasm to the Bone Modeling Modification Morbidity - disease rate Nervous System Physiology Neurologic Neurology Neurons Nitric Oxide Outcome Pathogenesis Patients Phase Phase II Clinical Trials Phase III Clinical Trials Platelet Activation Play Preclinical Testing Production Property Prostaglandins I Proteins Rattus Recovery Regimen Reperfusion Injury Research Rest Risk Role Safety Secondary Prevention Secure Serum Staging Stroke Texas Therapeutic Therapeutic Effect Thromboxanes Time Tissues Universities abciximab base brain tissue clinically relevant clopidogrel design disability effective therapy efficacy testing fluidity gastrointestinal improved interest meetings mortality neuroprotection novel percutaneous coronary intervention public health relevance research study stroke therapy

项目摘要

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. We will validate hypothesis that in thromboembolic model of stroke in rats, combination treatment of ASA plus apyrase at acute stage provides more effective protection than ASA or apyrase alone in short term as well as long-term experiments without increasing intracerebral hemorrhage. PUBLIC HEALTH RELEVANCE: We will utilize clinically relevant embolic stroke models in rats to assess neuroprotective effect of aspirin and apyrase treatment.

描述（由申请人提供）：人腺苷三磷酸双磷酸酶是治疗急性缺血性卒中的一种非常有前途的疗法，急性缺血性卒中是导致死亡和残疾的主要原因，对大多数患者几乎没有有效的疗法。这种酶强烈抑制血小板活化和聚集，具有适度的出血风险。我们将验证以下假设：在大鼠卒中血栓栓塞模型中，在急性期联合阿萨和腺苷三磷酸双磷酸酶治疗在短期和长期实验中提供比单独阿萨或腺苷三磷酸双磷酸酶更有效的保护，而不增加脑出血。公共卫生相关性：我们将在大鼠中利用临床相关的栓塞性中风模型来评估阿司匹林和腺苷三磷酸双磷酸酶治疗的神经保护作用。